Sign in Subscribe
Stock offerings

Neola Medical AB Achieves Key Milestones in Q1 2025

Strategic Insights

— 1 min read

Neola Medical AB made significant progress in the first quarter of 2025, strengthening its financial position through a directed share issue and advancing its clinical pilot study in Sweden. The company successfully included a baby in its clinical pilot study, marking the first time its Neola(r) technology has been used to monitor the lungs of a baby in a neonatal intensive care setting. Neola Medical also secured patent grants in Europe and China, reinforcing its intellectual property portfolio. The company's CEO, [Name], highlighted the importance of these milestones, emphasizing the long-term confidence in Neola Medical and its ambition to deliver sustainable value.

Key Takeaways:

  • Neola Medical AB conducted a successful directed share issue of approximately SEK 20 million, attracting new institutional investors including Cicero Fonder and Adrigo Fonder.
  • The company reached a major clinical milestone with the successful inclusion of a baby in its ongoing clinical pilot study in Sweden, marking the first time its Neola(r) technology has been used to monitor the lungs of a baby in a neonatal intensive care setting.
  • Neola Medical received patent grants in Europe and China, two strategically important markets, further strengthening the protection of its core medical technology.
  • The company was named one of eight finalists for the Pioneer Prize, Sweden's new global innovation award, presented at the World Expo 2025 in Osaka, Japan.
  • Neola Medical AB demonstrated a strong and expanding IP position, reinforcing its competitive edge as it advances through clinical development.
  • The company's clinical pilot study in Sweden provides valuable insights into the use of Neola(r) technology in its target patient group, contributing to the refinement of the technology and preparation for its pivotal clinical study in the U.S.

Statistics:

  • Net operating revenue: SEK 0k (0)
  • Operating result: SEK -2.712k (-2.568)
  • Cash flow for the period: SEK 13.110k (13.568)
  • Result per share: -0.04 SEK (-0.04)

Sources:

  • Neola Medical AB, Press Release: "Neola Medical AB: Q1 Report 2025" (2025)
  • Svenska Handelsbanken AB, Report: "Accelerated Bookbuilding Procedure" (2025)

Read more